Mufg Securities Americas Inc. Purchases 4,319 Shares of AbbVie Inc. $ABBV

Key Points

• Mufg Securities Americas increased its AbbVie stake by 8.8% in the second quarter, acquiring 4,319 shares for a total holding of 53,213 shares valued at approximately $13.4 million. Institutional investors own 70.23% of AbbVie.
• Analysts remain broadly bullish, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $275.95; several firms recently raised targets to $288–$300.
• AbbVie exceeded quarterly expectations with $3.65 in EPS and $16.99 billion in revenue, while reporting 10.2% year-over-year revenue growth. The company also declared a quarterly dividend of $1.73 per share, representing a 2.7% annualized yield.

Mufg Securities Americas Inc. grew its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 8.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,213 shares of the company's stock after acquiring an additional 4,319 shares during the quarter. AbbVie accounts for 0.7% of Mufg Securities Americas Inc.'s holdings, making the stock its 24th biggest position. Mufg Securities Americas Inc.'s holdings in AbbVie were worth $13,391,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC grew its position in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its position in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC raised its stake in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock worth $637,000 after acquiring an additional 43 shares in the last quarter. Finally, Bank of Jackson Hole Trust lifted its position in AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock valued at $1,648,000 after acquiring an additional 44 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ABBV. Morgan Stanley restated an "overweight" rating and issued a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Wolfe Research raised AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Canaccord Genuity Group raised their price objective on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Guggenheim boosted their target price on AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

AbbVie Trading Down 0.1%

Shares of AbbVie stock opened at $256.27 on Tuesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The firm's 50 day simple moving average is $254.71 and its two-hundred day simple moving average is $230.21.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie's payout ratio is currently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.